Beta bionics announces fourth quarter and full year 2024 financial results and introduces annual guidance for full year 2025

Irvine, calif., march 25, 2025 (globe newswire) -- beta bionics, inc. (nasdaq: bbnx), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended december 31, 2024 and introduced its annual guidance for the year ending december 31, 2025.
BBNX Ratings Summary
BBNX Quant Ranking